WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature journal ...
WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 American ...
Presentations at the 37th Annual European Association of Urology Congress to Demonstrate Measurable and Sustained Improvement of BPH Symptoms and IPSS Scores WAYNE, Pa., July 01, 2022 (GLOBE NEWSWIRE) ...
Men with lower urinary tract symptoms linked to an enlarged prostate report better outcomes from a surgical implant than with a commonly prescribed drug for the condition, according to new data ...
In a ground-breaking medical achievement, Nigeria has become the first country in West and Central Africa to successfully perform the UroLift procedure, a revolutionary treatment for benign prostate ...
DEAR DR. ROACH: I’m 79, and for several years, I have been taking finasteride and tamsulosin for benign prostatic hyperplasia. (In the past, I underwent a TURP procedure, which I will never go through ...
UroLift is a minimally invasive treatment option for benign prostatic hyperplasia (BPH), also called enlarged prostate. Medicare covers the UroLift procedure when a doctor deems it medically necessary ...
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has unveiled groundbreaking results from the CLEAR study, the first head-to-head randomized controlled trial comparing the UroLift™ System with Rezūm™ ...
Source: Getty Images Patients who underwent the minimally invasive procedure had a 36%, 50%, and 44% improvement in IPSS, quality of life, and peak flow rate, respectively, at 5 years. Prostatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results